| 
		  | 
					
						| Zacks Company Profile for Pfizer Inc. (PFE : NYSE) |  |  | 
|  | 
| 
		  | 
					
						|  Company Description |  
						| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Number of Employees: 81,000 |  |  | 
|  | 
| 
		  | 
					
						|  Price / Volume Information |  
						| Yesterday's Closing Price: $24.29 | Daily Weekly Monthly 
  |  
						| 20 Day Moving Average: 52,847,232 shares |  
						| Shares Outstanding: 5,685.55 (millions) |  
						| Market Capitalization: $138,102.03 (millions) |  
						| Beta: 0.55 |  
						| 52 Week High: $28.54 |  
						| 52 Week Low: $20.92 |  
						| Short Interest Ratio: |  
						| 
							| 
										
											|  | % Price Change | % Price Change Relative to S&P 500 |  
											| 4 Week | -10.30% | -11.71% |  
											| 12 Week | 0.25% | -6.84% |  
											| Year To Date | -8.44% | -21.07% |  |  |  |  | 
|  | 
| 
		  | 
					
						|  Address & Contact Information |  
						| Street Address | Phone / Fax | Email Address | Web URL |  
						| 66 HUDSON BOULEVARD EAST -
 NEW YORK,NY 10001
 USA
 | ph: 212-733-2323 fax: 302-655-5049
 | ir@pfizer.com | http://www.pfizer.com |  |  | 
|  | 
| 
		  | 
					
						|  General Corporate Information |  
						| Officers 
 
							| Albert Bourla   - Chief Executive Officer; Chairman and Director David M. Denton   - Chief Financial Officer and Executive Vice Preside
 Jennifer B. Damico   - Senior Vice President and Controller
 Ronald E. Blaylock   - Director
 Mortimer J. Buckley   - Director
 
								  |  | Peer Information 
 
							| Pfizer Inc. (AGN.) Pfizer Inc. (NVS)
 Pfizer Inc. (NVO)
 Pfizer Inc. (LLY)
 Pfizer Inc. (RHHBY)
 Pfizer Inc. (JNJ)
 |  |  
						| Industry / Sector / Ticker Info 
 
							 | Analyst Coverage: No Industry Group: Large Cap Pharma
 Sector: Medical
 CUSIP: 717081103
 SIC: 2834
 |  | Fiscal Year 
 
							 | Fiscal Year End: December Last Reported Quarter: 06/01/25
 Next Expected EPS Date: 11/04/25
 |  |  
						| Share - Related Items 
 
							 | Shares Outstanding: 5,685.55 Most Recent Split Date: 7.00 (3.00:1)
 Beta: 0.55
 Market Capitalization: $138,102.03 (millions)
 |  |  |  |  | 
|  | 
| 
		  | 
					
						|  EPS Information |  Dividend Information |  
						| Analyst Coverage: No | Dividend Yield: 7.08% |  
						| Current Fiscal Quarter EPS Consensus Estimate: $0.72 | Indicated Annual Dividend: $1.72 |  
						| Current Fiscal Year EPS Consensus Estimate: $3.05 | Payout Ratio: 0.51 |  
						| Number of Estimates in the Fiscal Year Consensus: 8.00 | Change In Payout Ratio: -0.03 |  
						| Estmated Long-Term EPS Growth Rate: 9.85% | Last Dividend Paid: NA - $0.00 |  
						| Next EPS Report Date: 11/04/25 |  |  |  | 
|  |